Non-Invasive Prenatal Testing Market - Global Market Analysis, Size, Volume, Share, Growth, Trends and Forecast 2011 – 2021; New Report Launched

Non-Invasive Prenatal Test (NIPT) are targeted at the detection of certain specific chromosomal aneuploidies from maternal blood sample in pregnant women at high risk for fetal aneuploidies. Currently, the prenatal testing market is experiencing a paradigm shift from conventional prenatal screening and diagnostic methods to non-invasive prenatal testing. This is mainly because of the advantages associated with NIPTs such as safety, accuracy, and no risk of miscarriage during the genetic screening test for common chromosomal abnormalities.

NIPT is one of the most promising new areas of screening because it delivers highly actionable insights for empowering critical health decisions. The global non-invasive prenatal testing market is segmented on the basis of tests viz; Harmony, MaterniT21 PLUS, PrenaTest, Verifi, BambniTest, Panorama, InformaSeq, Non-Invasive Fetal Trisomy Test (NIFTY), VisibiliT, Veracity and IONA Test. NIPT has experienced substantial growth over the past few years.

MaterniT21 plus test has gain its momentum in 2011 when there was only one NIPT test available in the market. In 2015, The MaterniT21 plus test market revenue decreased with XXX% compared to 2014. MaterniT21 test market revenue value was US$ XXX Million in 2015. Natera has emerged as one of the leading companies, with innovative technologies and a strong commercial base. Natera Panorama test will lead the NIPT market in the forecasting period with the market share of XXX% by the year 2021. Other NIPT tests such as Harmony, Verifi and NIFTY have emerged as the promising test in the NIPT test market. The major companies are expanding their tests through Collaboration, Distribution Agreement, Strategic Alliances and Partnerships with Clinical Laboratories and Hospitals.

The report titled Non-Invasive Prenatal Testing (NIPT) Market (Panorama, Bambni Test, Harmony, MaterniT21 PLUS, NIFTY, PrenaTest, Verifi, VisibiliT, informaSeq, Veracity, IONA Test) - Global Market Analysis, Size, Volume, Share, Growth, Trends and Forecast 2011 – 2021. The report presents a comprehensive study of the Global NIPT market with market revenue and volume of the tests. market shares for leading NIPT test, comparative analysis of the non–invasive prenatal testing, NIPT implementation in HICs and LMICs, major deals in the NIPT market such as Collaborations, Partnerships, Distribution Agreement, Venture Capital Investment, Merger & Acquisition, Licensing Agreement and Exclusive Agreement. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market

Key segments of the Global NIPT market

The 11 NIPT Test covered in the report has been analyzed from 2 viewpoints:

1. NIPT Test Market Revenue (2011 - 2021)

2. NIPT Test Volume (2011 - 2021)

The following are the NIPT test name which is covered in the report.

1) BambniTest

2) Harmony

3) informaSeq

4) MaterniT21 PLUS

5) NIFTY

6) Panorama

7) PrenaTest

8) verifi

9) VisibiliT

10) Veracity

11) IONA Test

The report also covers NIPT implementation in High Income Countries and Low - or- Middle Income Countries. The 3 issues for implementation covered are:

1) Clinical Issues

2) Ethical Issues

3) Legal and Regulatory Issues

This report gives access to significant data such as:

• Market Growth Drivers
• Challenges in the NIPT Test Market
• Current Market Trends
• Market Forecasting for the Coming Years
• Comparative Test Analysis

Data Sources

The information contained in this report is based on both primary and secondary sources.

Primary Sources: Questionnaires, Surveys, telephonic interviews with industry experts and Observations

Secondary Sources: Secondary data analysis and review involves collecting and analysing a vast array of information. Publisher seeks information from different sources such as published articles, company websites, magazine articles, associations, trade journals, annual reports, Newspapers, Books, Government official websites and other paid database sources.

Spanning over 118 pages “Non-Invasive Prenatal Testing (NIPT) Market (Panorama, Bambni Test, Harmony, MaterniT21 PLUS, NIFTY, PrenaTest, Verifi, VisibiliT, informaSeq, Veracity, IONA Test) - Global Market Analysis, Size, Volume, Share, Growth, Trends and Forecast 2011 – 2021” report covers Executive Summary, Global Non–Invasive Prenatal Testing Market Analysis (2011 – 2021), Global Non–Invasive Prenatal Testing Market Share Analysis (2011 – 2021), Global Non–Invasive Prenatal Testing(NIPT) – Comparative Tests Analysis, Global Non–Invasive Prenatal Testing Market Revenue & Volume – By Test (2011 – 2021), Major Deals – Global Non–Invasive Prenatal Testing Market, Non–Invasive Prenatal Testing (NIPT) Implementation, Global Non–Invasive Prenatal Testing – Market Drivers, Global Non–Invasive Prenatal Testing – Challenges.

For more information Visit at: http://mrr.cm/J5z

Find all Diagnostics report at: http://www.marketresearchreports.com/diagnostics

Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies; New Report Launched

Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies provides key insights into the global telehealth regulatory and market landscape, as well as its main applications in healthcare and associated sectors.

The continued adoption of telehealth technologies around the world will have a positive impact, not only on healthcare markets, but on a range of different sectors as well. The report assesses the potential impact these technologies will have on healthcare systems as well the business opportunities they offer to other industries – including the technology and telecommunications sectors. Furthermore, the analysis explores recent developments in regulations and guidelines in key geographies including the US, Europe, Japan, China, India and South Africa. Along with global market drivers and restraints, the report also provides insights into the size of telehealth/telecare markets in key geographical markets.

Many healthcare providers have developed integrated strategies for adopting telehealth technologies, particularly as their value continues to be quantified. Detailed case studies of recent successful telehealth programs are provided in this new report, showcasing strategies and the impact these have had on patients and healthcare systems. The analysis shows that successful telehealth programs will tend to implement careful and detailed planning, considering all key stakeholders and available engagement channels while integrating appropriate services across them. Important operational strategies to consider when planning and implementing a new telehealth program are also outlined in dedicated sections of the report.

mHealth technologies and telemedicine devices are being increasingly adopted globally, and represent the most rapidly growing fields within telehealth. In particular, the introduction of easily worn biosensors has sparked a great deal of interest in this sector in recent years. Profiles and product descriptions of novel technologies within these two fast-growing telehealth segments are provided, along with an outline of challenges and business opportunities.

Publisher has conducted extensive research in order to provide a comprehensive view of the global market trends in the telehealth industry. These unique and trusted industry analyses will enable a complete understanding of the telehealth market in both established and emerging markets.

Scope

• What impact will telehealth technologies have on healthcare systems, patients and related sectors?
• What strategies are healthcare providers considering when implementing new telehealth programs?
• How does the telehealth regulatory and market landscape compare in the developed markets of the US, Europe and Japan, compared with that of emerging economies like India, China and South Africa?
• What technological, macroeconomic and industry factors are driving or restraining the telehealth market?
• What are the most important factors to consider when designing and implementing a new telehealth program?
• What are the most pertinent considerations for all telehealth programs?
• What telehealth devices represent the biggest commercial opportunities and what are their key features?

Reasons to buy

This report will allow you to -

• Gain unique insights into the regulatory landscape of the telehealth sector in key geographical markets including the US, Europe, China, Japan, India and South Africa: This report comprehensively describes and assesses recent regulatory developments and telehealth guidelines in this dynamic sector.
• Assess the most pertinent commercial trends in the telehealth sector: This report provides global market drivers, restraints and market size and growth estimates for key geographical markets, providing insights into novel product technologies and those garnering significant adoption.
• Assess operational strategies for telehealth program design and implementation: This report provides insights and recommendations to consider when implementing a new telehealth program, including market research, HR, channel analysis, governance, revenue models, monitoring and security considerations.
• Assess novel technologies in key telehealth sectors: This report also provides a comprehensive analysis including trends, challenges and opportunities for telemedicine devices and mHealth technologies, providing insights into novel product technologies and those garnering significant adoption around the world.

Spanning over 64 pages “Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies” report covers Executive Summary, Introduction, Impact of Telehealth Technologies on Healthcare Systems and Patients, Evolving Telehealth Regulations, Telehealth Market Drivers, Telemedicine Devices, Key Manufacturers, Appendix.

For more information Visit at: http://mrr.cm/J5E

Find all IT and eHealth report at: http://www.marketresearchreports.com/it-ehealth

Asthma Therapeutics in Asia-Pacific Markets to 2021; New Report Launched

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

• What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

• Which classes of novel drugs are most prominent within the pipeline?
• Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

• How do failure rates vary by product stage of development, molecule type, and mechanism of action?
• How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?
• Will new market entrants lead to substantial changes in annual therapy costs?
• How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

• Will affordability threaten the commercial success of existing drugs as well as newer biologics?
• Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -

• Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
• Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
• Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
• Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
• Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Spanning over 130 pages “Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns” report covers Introduction, Marketed Products, Pipeline Analysis, Clinical Trial Analysis, Multi-Scenario Forecast, Drivers and Barriers, Deals and Strategic Consolidations, Appendix.

For more information Visit at: http://mrr.cm/J5R

Find all Diseases report at: http://www.marketresearchreports.com/diseases